Last 12 months
Inside the activity.
9 purchase rows · 6 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 1 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 1 | 0 |
| Mar 2026 | 5 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 2 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2021 Filed Feb 18, 2021 02:14 UTC |
Johnson Jennifer AmyEVP, General Counsel
|
Exercise / conversionCommon Stock | 365 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002880 · doc4.xml · nonDerivative · entry 1 Johnson Jennifer Amy · CIK 0001844366 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects vesting and settlement of Restricted Stock Units ("RSUs") granted on February 14, 2019. F2 · price: The RSUs convert to Common Stock on a one-for-one basis. Read SEC document |
| February 14, 2021 Filed Feb 20, 2021 00:00 UTC Amendment |
Strzelecki AngelaPresident, Pharma Solutions
|
Exercise / conversionRestricted Stock Units · Derivative | 365 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003226 · doc4a.xml · derivative · entry 1 Strzelecki Angela · CIK 0001843595 · President, Pharma Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,119 Underlying: Common Stock · 365 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The RSUs convert to Common Stock on a one-for-one basis. F2 · shares: Reflects vesting and settlement of Restricted Stock Units ("RSUs") granted on February 14, 2019. F1 · price: The RSUs convert to Common Stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs vested on February 14, 2021. F3 · derivative.expiration_date: The RSUs vested on February 14, 2021. F4 · balance_after: Number of RSUs was misreported due to administrative error. Read SEC document |
| February 14, 2021 Filed Feb 19, 2021 23:59 UTC Amendment |
Johnson Jennifer AmyEVP, General Counsel
|
Exercise / conversionRestricted Stock Units · Derivative | 365 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003225 · doc4a.xml · derivative · entry 1 Johnson Jennifer Amy · CIK 0001844366 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,490 Underlying: Common Stock · 365 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The RSUs convert to Common Stock on a one-for-one basis. F2 · shares: Reflects vesting and settlement of Restricted Stock Units ("RSUs") granted on February 14, 2019. F1 · price: The RSUs convert to Common Stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs vested on February 14, 2021. F3 · derivative.expiration_date: The RSUs vested on February 14, 2021. F4 · balance_after: Number of RSUs was misreported due to administrative error. Read SEC document |
| February 14, 2021 Filed Feb 19, 2021 23:59 UTC Amendment |
Herriott SimonPresident Health & Biosciences
|
Exercise / conversionRestricted Stock Units · Derivative | 525 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003224 · doc4a.xml · derivative · entry 1 Herriott Simon · CIK 0001843592 · President Health & Biosciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,374 Underlying: Common Stock · 525 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The RSUs convert to Common Stock on a one-for-one basis. F2 · shares: Reflects vesting and settlement of Restricted Stock Units ("RSUs") granted on February 14, 2019. F1 · price: The RSUs convert to Common Stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs vested on February 14, 2021. F3 · derivative.expiration_date: The RSUs vested on February 14, 2021. F4 · balance_after: Number of RSUs was misreported due to administrative error. Read SEC document |
| February 14, 2021 Filed Jun 2, 2021 20:46 UTC Amendment |
Herriott SimonPresident Health & Biosciences
|
Tax withholdingCommon Stock | 132 | $136.21 | $17,979.72 |
DisclosureSEC source: 0001225208-21-008817 · doc4a.xml · nonDerivative · entry 1 Herriott Simon · CIK 0001843592 · President Health & Biosciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 874 F1 · shares: Reflects shares withheld for taxes payable upon the vesting of RSUs. Number of shares withheld was misreported due to administrative error. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 02:14 UTC |
Fibig AndreasDirector · CEO
|
GrantStock Equivalent Unit · Derivative | 50.506 | $134.06 | $6,770.83 |
DisclosureSEC source: 0001225208-21-002879 · doc4.xml · derivative · entry 2 Fibig Andreas · CIK 0001514412 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,009.996 Underlying: Common Stock · 50.506 shares Expires not disclosed F1 · derivative.exercise_price: The Stock Equivalent Units ("Units") convert to Common Stock on a one-for-one basis. F2 · shares: Reflects Units under the Company's deferred compensation plan resulting from deferral of compensation and the 25% premium contributed by the Company on such Units. Units contributed by the Company are subject to vesting based on continued employment through December 31, 2022. F3 · derivative.exercise_date: The Units are payable in Common Stock upon earlier of termination of employment or January 1 following retirement. F3 · derivative.expiration_date: The Units are payable in Common Stock upon earlier of termination of employment or January 1 following retirement. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 02:14 UTC |
Jilla RustomCFO
|
GrantStock Equivalent Unit · Derivative | 17.716 | $134.06 | $2,375.01 |
DisclosureSEC source: 0001225208-21-002878 · doc4.xml · derivative · entry 2 Jilla Rustom · CIK 0001648161 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399.512 Underlying: Common Stock · 17.716 shares Expires not disclosed F1 · derivative.exercise_price: The Stock Equivalent Units ("Units") convert to Common Stock on a one-for-one basis. F2 · shares: Reflects Units under the Company's deferred compensation plan resulting from deferral of compensation and the 25% premium contributed by the Company on such Units. Units contributed by the Company are subject to vesting based on continued employment through December 31, 2022. F3 · derivative.exercise_date: The Units are payable in Common Stock upon earlier of termination of employment or January 1 following retirement. F3 · derivative.expiration_date: The Units are payable in Common Stock upon earlier of termination of employment or January 1 following retirement. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 02:14 UTC |
Anderson Robert G.Controller
|
GrantStock Equivalent Unit · Derivative | 10.198 | $134.06 | $1,367.14 |
DisclosureSEC source: 0001225208-21-002877 · doc4.xml · derivative · entry 2 Anderson Robert G. · CIK 0001692622 · Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,343.428 Underlying: Common Stock · 10.198 shares Expires not disclosed F1 · derivative.exercise_price: The Stock Units ("Units") convert to Common Stock on a one-for-one basis. F2 · shares: Reflects Units under the Company's deferred compensation plan resulting from deferral of compensation and the 25% premium contributed by the Company on such Units. Units contributed by the Company are subject to vesting based on continued employment through December 31, 2022. F3 · derivative.exercise_date: The Units are payable in Common Stock upon earlier of termination of employment or January 1 following retirement. F3 · derivative.expiration_date: The Units are payable in Common Stock upon earlier of termination of employment or January 1 following retirement. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 00:21 UTC |
DUCKER MICHAEL LDirector
|
Exercise / conversionStock Equivalent Unit · Derivative | 7,668 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-21-002467 · doc4.xml · derivative · entry 2 DUCKER MICHAEL L · CIK 0001188170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,668 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents Stock Equivalent Units (the "Units") acquired under the Company's deferred compensation plan (the "DCP") previously reported. Each Unit converts to Common Stock on a one-for-one basis. On February 10, 2021, the Units were distributed from the DCP for an equal number of shares of Common Stock. F2 · shares: Includes Units acquired during the period upon reinvestment of dividends under the Company's deferred compensation plan since the last report. The transactions were exempt pursuant to Rule 16a-11. F1 · price: Represents Stock Equivalent Units (the "Units") acquired under the Company's deferred compensation plan (the "DCP") previously reported. Each Unit converts to Common Stock on a one-for-one basis. On February 10, 2021, the Units were distributed from the DCP for an equal number of shares of Common Stock. F1 · derivative.exercise_date: Represents Stock Equivalent Units (the "Units") acquired under the Company's deferred compensation plan (the "DCP") previously reported. Each Unit converts to Common Stock on a one-for-one basis. On February 10, 2021, the Units were distributed from the DCP for an equal number of shares of Common Stock. F1 · derivative.expiration_date: Represents Stock Equivalent Units (the "Units") acquired under the Company's deferred compensation plan (the "DCP") previously reported. Each Unit converts to Common Stock on a one-for-one basis. On February 10, 2021, the Units were distributed from the DCP for an equal number of shares of Common Stock. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 00:21 UTC |
DUCKER MICHAEL LDirector
|
Exercise / conversionCommon Stock | 7,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002467 · doc4.xml · nonDerivative · entry 1 DUCKER MICHAEL L · CIK 0001188170 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents Stock Equivalent Units (the "Units") acquired under the Company's deferred compensation plan (the "DCP") previously reported. Each Unit converts to Common Stock on a one-for-one basis. On February 10, 2021, the Units were distributed from the DCP for an equal number of shares of Common Stock. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:59 UTC |
Johnson Jennifer AmyEVP, General Counsel
|
GrantStock Options (right to buy) · Derivative | 11,702 | Not disclosed Strike: $95.28 | Not disclosed |
DisclosureSEC source: 0001225208-21-001615 · doc4.xml · derivative · entry 7 Johnson Jennifer Amy · CIK 0001844366 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,702 Underlying: Common Stock · 11,702 shares Expires 2029-08-05 F5 · price: In connection with the Transactions, DuPont options were replaced with Options to purchase Common Stock. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:59 UTC |
Johnson Jennifer AmyEVP, General Counsel
|
GrantStock Options (right to buy) · Derivative | 9,411 | Not disclosed Strike: $77.16 | Not disclosed |
DisclosureSEC source: 0001225208-21-001615 · doc4.xml · derivative · entry 6 Johnson Jennifer Amy · CIK 0001844366 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,411 Underlying: Common Stock · 9,411 shares Expires 2030-02-18 F5 · price: In connection with the Transactions, DuPont options were replaced with Options to purchase Common Stock. F6 · derivative.exercise_date: Options will vest and become exercisable in three equal tranches with respect to 3137 shares of Common Stock on each of February 19, 2021, 2022 and 2023, subject to continued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:59 UTC |
Johnson Jennifer AmyEVP, General Counsel
|
GrantStock Options (right to buy) · Derivative | 2,241 | Not disclosed Strike: $149.65 | Not disclosed |
DisclosureSEC source: 0001225208-21-001615 · doc4.xml · derivative · entry 5 Johnson Jennifer Amy · CIK 0001844366 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,241 Underlying: Common Stock · 2,241 shares Expires 2028-02-14 F5 · price: In connection with the Transactions, DuPont options were replaced with Options to purchase Common Stock. F4 · derivative.exercise_date: Option is exercisable as of the date of replacement with respect to 1494 shares of Common Stock. The Option will become exercisable in respect of the remaining 747 shares of Common Stock on February 15, 2021, subject to continued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:59 UTC |
Johnson Jennifer AmyEVP, General Counsel
|
GrantRestricted Stock Units · Derivative | 3,241 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-21-001615 · doc4.xml · derivative · entry 4 Johnson Jennifer Amy · CIK 0001844366 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,241 Underlying: Common Stock · 3,241 shares Expires 2021-12-31 F1 · derivative.exercise_price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F1 · price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:59 UTC |
Johnson Jennifer AmyEVP, General Counsel
|
GrantRestricted Stock Units · Derivative | 58 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-21-001615 · doc4.xml · derivative · entry 3 Johnson Jennifer Amy · CIK 0001844366 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58 Underlying: Common Stock · 58 shares Expires 2021-02-15 F1 · derivative.exercise_price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F1 · price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:59 UTC |
Johnson Jennifer AmyEVP, General Counsel
|
GrantRestricted Stock Units · Derivative | 1,462 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-21-001615 · doc4.xml · derivative · entry 2 Johnson Jennifer Amy · CIK 0001844366 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,834 Underlying: Common Stock · 1,462 shares Expires not disclosed F1 · derivative.exercise_price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F1 · price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F3 · derivative.exercise_date: RSU vests with respect to 731 shares of Common Stock on each of February 14, 2021 and 2022, subject to continued employment with IFF. F3 · derivative.expiration_date: RSU vests with respect to 731 shares of Common Stock on each of February 14, 2021 and 2022, subject to continued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:59 UTC |
Johnson Jennifer AmyEVP, General Counsel
|
GrantRestricted Stock Units · Derivative | 6,372 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-21-001615 · doc4.xml · derivative · entry 1 Johnson Jennifer Amy · CIK 0001844366 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,372 Underlying: Common Stock · 6,372 shares Expires not disclosed F1 · derivative.exercise_price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F1 · price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F2 · derivative.exercise_date: RSUs vest in three equal tranches with respect to 2124 shares of Common Stock on each of February 19, 2021, 2022 and 2023, subject to continued employment with IFF. F2 · derivative.expiration_date: RSUs vest in three equal tranches with respect to 2124 shares of Common Stock on each of February 19, 2021, 2022 and 2023, subject to continued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:58 UTC |
Herriott SimonPresident Health & Biosciences
|
GrantStock Options (right to buy) · Derivative | 11,702 | Not disclosed Strike: $95.28 | Not disclosed |
DisclosureSEC source: 0001225208-21-001613 · doc4.xml · derivative · entry 9 Herriott Simon · CIK 0001843592 · President Health & Biosciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,702 Underlying: Common Stock · 11,702 shares Expires 2029-08-05 F5 · price: In connection with the Transactions, DuPont options were replaced with Options to purchase Common Stock. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:58 UTC |
Herriott SimonPresident Health & Biosciences
|
GrantStock Options (right to buy) · Derivative | 1,513 | Not disclosed Strike: $115.48 | Not disclosed |
DisclosureSEC source: 0001225208-21-001613 · doc4.xml · derivative · entry 8 Herriott Simon · CIK 0001843592 · President Health & Biosciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,513 Underlying: Common Stock · 1,513 shares Expires 2022-02-03 F5 · price: In connection with the Transactions, DuPont options were replaced with Options to purchase Common Stock. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:58 UTC |
Herriott SimonPresident Health & Biosciences
|
GrantStock Options (right to buy) · Derivative | 9,606 | Not disclosed Strike: $123.76 | Not disclosed |
DisclosureSEC source: 0001225208-21-001613 · doc4.xml · derivative · entry 7 Herriott Simon · CIK 0001843592 · President Health & Biosciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,606 Underlying: Common Stock · 9,606 shares Expires 2027-02-01 F5 · price: In connection with the Transactions, DuPont options were replaced with Options to purchase Common Stock. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:58 UTC |
Herriott SimonPresident Health & Biosciences
|
GrantStock Options (right to buy) · Derivative | 8,469 | Not disclosed Strike: $77.16 | Not disclosed |
DisclosureSEC source: 0001225208-21-001613 · doc4.xml · derivative · entry 6 Herriott Simon · CIK 0001843592 · President Health & Biosciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,469 Underlying: Common Stock · 8,469 shares Expires 2030-02-18 F5 · price: In connection with the Transactions, DuPont options were replaced with Options to purchase Common Stock. F6 · derivative.exercise_date: Options will vest and become exercisable in three equal tranches with respect to 2,823 shares of Common Stock on each of February 19, 2021, 2022 and 2023, subject to contiued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:58 UTC |
Herriott SimonPresident Health & Biosciences
|
GrantStock Options (right to buy) · Derivative | 4,068 | Not disclosed Strike: $149.65 | Not disclosed |
DisclosureSEC source: 0001225208-21-001613 · doc4.xml · derivative · entry 5 Herriott Simon · CIK 0001843592 · President Health & Biosciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,068 Underlying: Common Stock · 4,068 shares Expires 2028-02-14 F5 · price: In connection with the Transactions, DuPont options were replaced with Options to purchase Common Stock. F4 · derivative.exercise_date: Option is exercisable as of the date of replacement with respect to 2,712 shares of Common Stock. The Option will become exercisable in respect of the remaining 1,356 shares of Common Stock on February 15, 2021, subject to continued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:58 UTC |
Herriott SimonPresident Health & Biosciences
|
GrantRestricted Stock Units · Derivative | 3,241 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-21-001613 · doc4.xml · derivative · entry 4 Herriott Simon · CIK 0001843592 · President Health & Biosciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,241 Underlying: Common Stock · 3,241 shares Expires 2021-12-31 F1 · derivative.exercise_price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F1 · price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:58 UTC |
Herriott SimonPresident Health & Biosciences
|
GrantRestricted Stock Units · Derivative | 105 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-21-001613 · doc4.xml · derivative · entry 3 Herriott Simon · CIK 0001843592 · President Health & Biosciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105 Underlying: Common Stock · 105 shares Expires 2021-02-15 F1 · derivative.exercise_price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F1 · price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:58 UTC |
Herriott SimonPresident Health & Biosciences
|
GrantRestricted Stock Units · Derivative | 2,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-21-001613 · doc4.xml · derivative · entry 2 Herriott Simon · CIK 0001843592 · President Health & Biosciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,647 Underlying: Common Stock · 2,100 shares Expires not disclosed F1 · derivative.exercise_price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F1 · price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F3 · derivative.exercise_date: RSU vests with respect to 1,050 shares of Common Stock on each of February 14, 2021 and 2022, subject to continued employment with IFF. F3 · derivative.expiration_date: RSU vests with respect to 1,050 shares of Common Stock on each of February 14, 2021 and 2022, subject to continued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:58 UTC |
Herriott SimonPresident Health & Biosciences
|
GrantRestricted Stock Units · Derivative | 5,547 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-21-001613 · doc4.xml · derivative · entry 1 Herriott Simon · CIK 0001843592 · President Health & Biosciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,547 Underlying: Common Stock · 5,547 shares Expires not disclosed F1 · derivative.exercise_price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F1 · price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F2 · derivative.exercise_date: RSUs vest in three equal tranches with respect to 1,849 shares of Common Stock on each of February 19, 2021, 2022 and 2023, subject to continued employment with IFF. F2 · derivative.expiration_date: RSUs vest in three equal tranches with respect to 1,849 shares of Common Stock on each of February 19, 2021, 2022 and 2023, subject to continued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:58 UTC |
Strzelecki AngelaPresident, Pharma Solutions
|
GrantStock Options (right to buy) · Derivative | 10,443 | Not disclosed Strike: $115.48 | Not disclosed |
DisclosureSEC source: 0001225208-21-001614 · doc4.xml · derivative · entry 7 Strzelecki Angela · CIK 0001843595 · President, Pharma Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,443 Underlying: Common Stock · 10,443 shares Expires 2022-02-03 F5 · price: In connection with the Transactions, DuPont options were replaced with Options to purchase Common Stock. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:58 UTC |
Strzelecki AngelaPresident, Pharma Solutions
|
GrantStock Options (right to buy) · Derivative | 6,375 | Not disclosed Strike: $123.76 | Not disclosed |
DisclosureSEC source: 0001225208-21-001614 · doc4.xml · derivative · entry 6 Strzelecki Angela · CIK 0001843595 · President, Pharma Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,375 Underlying: Common Stock · 6,375 shares Expires 2027-02-01 F5 · price: In connection with the Transactions, DuPont options were replaced with Options to purchase Common Stock. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:58 UTC |
Strzelecki AngelaPresident, Pharma Solutions
|
GrantStock Options (right to buy) · Derivative | 7,764 | Not disclosed Strike: $77.16 | Not disclosed |
DisclosureSEC source: 0001225208-21-001614 · doc4.xml · derivative · entry 5 Strzelecki Angela · CIK 0001843595 · President, Pharma Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,764 Underlying: Common Stock · 7,764 shares Expires 2030-02-18 F5 · price: In connection with the Transactions, DuPont options were replaced with Options to purchase Common Stock. F6 · derivative.exercise_date: Options will vest and become exercisable in three equal tranches with respect to 2,588 shares of Common Stock on each of February 19, 2021, 2022 and 2023, subject to continued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:58 UTC |
Strzelecki AngelaPresident, Pharma Solutions
|
GrantStock Options (right to buy) · Derivative | 3,138 | Not disclosed Strike: $149.65 | Not disclosed |
DisclosureSEC source: 0001225208-21-001614 · doc4.xml · derivative · entry 4 Strzelecki Angela · CIK 0001843595 · President, Pharma Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,138 Underlying: Common Stock · 3,138 shares Expires 2028-02-14 F5 · price: In connection with the Transactions, DuPont options were replaced with Options to purchase Common Stock. F4 · derivative.exercise_date: Option is exercisable as of the date of replacement with respect to 2,092 shares of Common Stock. The Option will become exercisable in respect of the remaining 1,046 shares of Common Stock on February 15, 2021, subjet to continued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:58 UTC |
Strzelecki AngelaPresident, Pharma Solutions
|
GrantRestricted Stock Units · Derivative | 81 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-21-001614 · doc4.xml · derivative · entry 3 Strzelecki Angela · CIK 0001843595 · President, Pharma Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81 Underlying: Common Stock · 81 shares Expires 2021-02-15 F1 · derivative.exercise_price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F1 · price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:58 UTC |
Strzelecki AngelaPresident, Pharma Solutions
|
GrantRestricted Stock Units · Derivative | 1,462 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-21-001614 · doc4.xml · derivative · entry 2 Strzelecki Angela · CIK 0001843595 · President, Pharma Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,721 Underlying: Common Stock · 1,462 shares Expires not disclosed F1 · derivative.exercise_price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F1 · price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F3 · derivative.exercise_date: RSUs vest with respect to 731 shares of Common Stock on each of February 14, 2021 and 2022, subject to continued employment with IFF. F3 · derivative.expiration_date: RSUs vest with respect to 731 shares of Common Stock on each of February 14, 2021 and 2022, subject to continued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:58 UTC |
Strzelecki AngelaPresident, Pharma Solutions
|
GrantRestricted Stock Units · Derivative | 5,259 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-21-001614 · doc4.xml · derivative · entry 1 Strzelecki Angela · CIK 0001843595 · President, Pharma Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,259 Underlying: Common Stock · 5,259 shares Expires not disclosed F1 · derivative.exercise_price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F1 · price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F2 · derivative.exercise_date: RSUs vest in three equal tranches with respect to 1,753 shares of Common Stock on each of February 19, 2021, 2022 and 2023, subject to continued employment with IFF. F2 · derivative.expiration_date: RSUs vest in three equal tranches with respect to 1,753 shares of Common Stock on each of February 19, 2021, 2022 and 2023, subject to continued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 23:56 UTC Amendment |
Strzelecki AngelaPresident, Pharma Solutions
|
GrantStock Options (right to buy) · Derivative | 3,481 | Not disclosed Strike: $115.48 | Not disclosed |
DisclosureSEC source: 0001225208-21-003223 · doc4a.xml · derivative · entry 6 Strzelecki Angela · CIK 0001843595 · President, Pharma Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,481 Underlying: Common Stock · 3,481 shares Expires 2022-02-03 F5 · shares: Number of Options was misreported due to administrative error. F7 · price: In connection with the Transactions, DuPont options were replaced with Options to purchase Common Stock. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 23:56 UTC Amendment |
Strzelecki AngelaPresident, Pharma Solutions
|
GrantStock Options (right to buy) · Derivative | 2,125 | Not disclosed Strike: $123.76 | Not disclosed |
DisclosureSEC source: 0001225208-21-003223 · doc4a.xml · derivative · entry 5 Strzelecki Angela · CIK 0001843595 · President, Pharma Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,125 Underlying: Common Stock · 2,125 shares Expires 2027-02-01 F5 · shares: Number of Options was misreported due to administrative error. F7 · price: In connection with the Transactions, DuPont options were replaced with Options to purchase Common Stock. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 23:56 UTC Amendment |
Strzelecki AngelaPresident, Pharma Solutions
|
GrantStock Options (right to buy) · Derivative | 2,588 | Not disclosed Strike: $77.16 | Not disclosed |
DisclosureSEC source: 0001225208-21-003223 · doc4a.xml · derivative · entry 4 Strzelecki Angela · CIK 0001843595 · President, Pharma Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,588 Underlying: Common Stock · 2,588 shares Expires 2030-02-18 F5 · shares: Number of Options was misreported due to administrative error. F7 · price: In connection with the Transactions, DuPont options were replaced with Options to purchase Common Stock. F8 · derivative.exercise_date: Options will vest and become exercisable in three equal tranches on each of February 19, 2021, 2022 and 2023, subject to continued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 23:56 UTC Amendment |
Strzelecki AngelaPresident, Pharma Solutions
|
GrantStock Options (right to buy) · Derivative | 1,046 | Not disclosed Strike: $149.65 | Not disclosed |
DisclosureSEC source: 0001225208-21-003223 · doc4a.xml · derivative · entry 3 Strzelecki Angela · CIK 0001843595 · President, Pharma Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,046 Underlying: Common Stock · 1,046 shares Expires 2028-02-14 F5 · shares: Number of Options was misreported due to administrative error. F7 · price: In connection with the Transactions, DuPont options were replaced with Options to purchase Common Stock. F6 · derivative.exercise_date: Option is exercisable as of the date of replacement with respect to 696 shares of Common Stock. The Option will become exercisable in respect of the remaining 350 shares of Common Stock on February 15, 2021, subject to continued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 23:56 UTC Amendment |
Strzelecki AngelaPresident, Pharma Solutions
|
GrantRestricted Stock Units · Derivative | 731 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-21-003223 · doc4a.xml · derivative · entry 2 Strzelecki Angela · CIK 0001843595 · President, Pharma Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,484 Underlying: Common Stock · 731 shares Expires not disclosed F1 · derivative.exercise_price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F2 · shares: Number of RSUs was misreported due to administrative error. F1 · price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F4 · derivative.exercise_date: RSUs vest in two equal tranches on each of February 14, 2021 and 2022, subject to continued employment with IFF. F4 · derivative.expiration_date: RSUs vest in two equal tranches on each of February 14, 2021 and 2022, subject to continued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 23:56 UTC Amendment |
Strzelecki AngelaPresident, Pharma Solutions
|
GrantRestricted Stock Units · Derivative | 1,753 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-21-003223 · doc4a.xml · derivative · entry 1 Strzelecki Angela · CIK 0001843595 · President, Pharma Solutions 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,753 Underlying: Common Stock · 1,753 shares Expires not disclosed F1 · derivative.exercise_price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F2 · shares: Number of RSUs was misreported due to administrative error. F1 · price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F3 · derivative.exercise_date: RSUs vest in three equal tranches on each of February 19, 2021, 2022 and 2023, subject to continued employment with IFF. F3 · derivative.expiration_date: RSUs vest in three equal tranches on each of February 19, 2021, 2022 and 2023, subject to continued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 23:56 UTC Amendment |
Johnson Jennifer AmyEVP, General Counsel
|
GrantStock Options (right to buy) · Derivative | 3,137 | Not disclosed Strike: $77.16 | Not disclosed |
DisclosureSEC source: 0001225208-21-003222 · doc4a.xml · derivative · entry 4 Johnson Jennifer Amy · CIK 0001844366 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,137 Underlying: Common Stock · 3,137 shares Expires 2030-02-18 F5 · shares: Number of Options was misreported due to administrative error. F7 · price: In connection with the Transactions, DuPont options were replaced with Options to purchase Common Stock. F8 · derivative.exercise_date: Options will vest and become exercisable in three equal tranches on each of February 19, 2021, 2022 and 2023, subject to continued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 23:56 UTC Amendment |
Johnson Jennifer AmyEVP, General Counsel
|
GrantStock Options (right to buy) · Derivative | 747 | Not disclosed Strike: $149.65 | Not disclosed |
DisclosureSEC source: 0001225208-21-003222 · doc4a.xml · derivative · entry 3 Johnson Jennifer Amy · CIK 0001844366 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 747 Underlying: Common Stock · 747 shares Expires 2028-02-14 F5 · shares: Number of Options was misreported due to administrative error. F7 · price: In connection with the Transactions, DuPont options were replaced with Options to purchase Common Stock. F6 · derivative.exercise_date: Option is exercisable as of the date of replacement with respect to 496 shares of Common Stock. The Option will become exercisable in respect of the remaining 251 shares of Common Stock on February 15, 2021, subject to continued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 23:56 UTC Amendment |
Johnson Jennifer AmyEVP, General Counsel
|
GrantRestricted Stock Units · Derivative | 731 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-21-003222 · doc4a.xml · derivative · entry 2 Johnson Jennifer Amy · CIK 0001844366 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,855 Underlying: Common Stock · 731 shares Expires not disclosed F1 · derivative.exercise_price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F2 · shares: Number of RSUs was misreported due to administrative error. F1 · price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F4 · derivative.exercise_date: RSUs vest in two equal tranches on each of February 14, 2021 and 2022, subject to continued employment with IFF. F4 · derivative.expiration_date: RSUs vest in two equal tranches on each of February 14, 2021 and 2022, subject to continued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 23:56 UTC Amendment |
Johnson Jennifer AmyEVP, General Counsel
|
GrantRestricted Stock Units · Derivative | 2,124 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-21-003222 · doc4a.xml · derivative · entry 1 Johnson Jennifer Amy · CIK 0001844366 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,124 Underlying: Common Stock · 2,124 shares Expires not disclosed F1 · derivative.exercise_price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F2 · shares: Number of RSUs was misreported due to administrative error. F1 · price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F3 · derivative.exercise_date: RSUs vest in three equal tranches on each of February 19, 2021, 2022 and 2023, subject to continued employment with IFF. F3 · derivative.expiration_date: RSUs vest in three equal tranches on each of February 19, 2021, 2022 and 2023, subject to continued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 23:56 UTC Amendment |
Herriott SimonPresident Health & Biosciences
|
GrantStock Options (right to buy) · Derivative | 3,202 | Not disclosed Strike: $123.76 | Not disclosed |
DisclosureSEC source: 0001225208-21-003221 · doc4a.xml · derivative · entry 5 Herriott Simon · CIK 0001843592 · President Health & Biosciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,202 Underlying: Common Stock · 3,202 shares Expires 2027-02-01 F5 · shares: Number of Options was misreported due to administrative error. F7 · price: In connection with the Transactions, DuPont options were replaced with Options to purchase Common Stock. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 23:56 UTC Amendment |
Herriott SimonPresident Health & Biosciences
|
GrantStock Options (right to buy) · Derivative | 2,823 | Not disclosed Strike: $77.16 | Not disclosed |
DisclosureSEC source: 0001225208-21-003221 · doc4a.xml · derivative · entry 4 Herriott Simon · CIK 0001843592 · President Health & Biosciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,823 Underlying: Common Stock · 2,823 shares Expires 2030-02-18 F5 · shares: Number of Options was misreported due to administrative error. F7 · price: In connection with the Transactions, DuPont options were replaced with Options to purchase Common Stock. F8 · derivative.exercise_date: Options will vest and become exercisable in three equal tranches on each of February 19, 2021, 2022 and 2023, subject to contiued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 23:56 UTC Amendment |
Herriott SimonPresident Health & Biosciences
|
GrantStock Options (right to buy) · Derivative | 1,356 | Not disclosed Strike: $149.65 | Not disclosed |
DisclosureSEC source: 0001225208-21-003221 · doc4a.xml · derivative · entry 3 Herriott Simon · CIK 0001843592 · President Health & Biosciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,356 Underlying: Common Stock · 1,356 shares Expires 2028-02-14 F5 · shares: Number of Options was misreported due to administrative error. F7 · price: In connection with the Transactions, DuPont options were replaced with Options to purchase Common Stock. F6 · derivative.exercise_date: Option is exercisable as of the date of replacement with respect to 904 shares of Common Stock. The Option will become exercisable in respect of the remaining 452 shares of Common Stock on February 15, 2021, subject to continued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 23:56 UTC Amendment |
Herriott SimonPresident Health & Biosciences
|
GrantRestricted Stock Units · Derivative | 1,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-21-003221 · doc4a.xml · derivative · entry 2 Herriott Simon · CIK 0001843592 · President Health & Biosciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,899 Underlying: Common Stock · 1,050 shares Expires not disclosed F1 · derivative.exercise_price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F2 · shares: Number of RSUs was misreported due to administrative error. F1 · price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F4 · derivative.exercise_date: RSUs vest in two equal tranches on each of February 14, 2021 and 2022, subject to continued employment with IFF. F4 · derivative.expiration_date: RSUs vest in two equal tranches on each of February 14, 2021 and 2022, subject to continued employment with IFF. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 23:56 UTC Amendment |
Herriott SimonPresident Health & Biosciences
|
GrantRestricted Stock Units · Derivative | 1,849 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001225208-21-003221 · doc4a.xml · derivative · entry 1 Herriott Simon · CIK 0001843592 · President Health & Biosciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,849 Underlying: Common Stock · 1,849 shares Expires not disclosed F1 · derivative.exercise_price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F2 · shares: Number of RSUs was misreported due to administrative error. F1 · price: In connection with the combination of IFF and the Nutrition & Biosciences business ("N&B") of DuPont de Nemours, Inc. ("DuPont") (the "Transactions"), DuPont restricted stock units were replaced with Restricted Stock Units ("RSUs") that convert into Common Stock on a one-for-one basis upon vesting. F3 · derivative.exercise_date: RSUs vest in three equal tranches on each of February 19, 2021, 2022 and 2023, subject to continued employment with IFF. F3 · derivative.expiration_date: RSUs vest in three equal tranches on each of February 19, 2021, 2022 and 2023, subject to continued employment with IFF. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 22:44 UTC |
Jilla RustomCFO
|
GrantStock Equivalent Unit · Derivative | 21.134 | $112.38 | $2,375.04 |
DisclosureSEC source: 0001225208-21-001463 · doc4.xml · derivative · entry 2 Jilla Rustom · CIK 0001648161 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381.796 Underlying: Common Stock · 21.134 shares Expires not disclosed F1 · derivative.exercise_price: The Stock Equivalent Units ("Units") convert to Common Stock on a one-for-one basis. F2 · shares: Reflects Units under the Company's deferred compensation plan resulting from deferral of compensation and the 25% premium contributed by the Company on such Units. Units contributed by the Company are subject to vesting based on continued employment through December 31, 2022. F3 · derivative.exercise_date: The Units are payable in Common Stock upon earlier of termination of employment or January 1 following retirement. F3 · derivative.expiration_date: The Units are payable in Common Stock upon earlier of termination of employment or January 1 following retirement. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 22:44 UTC |
Fibig AndreasDirector · CEO
|
GrantStock Equivalent Unit · Derivative | 60.25 | $112.38 | $6,770.90 |
DisclosureSEC source: 0001225208-21-001462 · doc4.xml · derivative · entry 2 Fibig Andreas · CIK 0001514412 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,959.49 Underlying: Common Stock · 60.25 shares Expires not disclosed F1 · derivative.exercise_price: The Stock Equivalent Units ("Units") convert to Common Stock on a one-for-one basis. F2 · shares: Reflects Units under the Company's deferred compensation plan resulting from deferral of compensation and the 25% premium contributed by the Company on such Units. Units contributed by the Company are subject to vesting based on continued employment through December 31, 2022. F3 · derivative.exercise_date: The Units are payable in Common Stock upon earlier of termination of employment or January 1 following retirement. F3 · derivative.expiration_date: The Units are payable in Common Stock upon earlier of termination of employment or January 1 following retirement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.